Asthma Clinical Trial
— AeroMUCOfficial title:
Effect of the Aerobika Oscillating Positive Expiratory Pressure (OPEP) Device on Mucus Plugging and Airflow Obstruction in Patients With Moderate-to-severe Asthma
The goal of this randomized clinical trial is to evaluate the effect of daily AerobikaTM Oscillating Positive Expiratory Pressure (OPEP) device use on mucus plugging and airway function in adult patients with moderate-to-severe asthma.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | July 1, 2025 |
Est. primary completion date | July 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Able and willing to provide written informed consent. 2. Able and willing to comply with the study protocol. 3. Males and females = 18 years of age. 4. Asthma diagnosed by a respiratory physician =12 months prior to study enrolment based on the Global Initiative for Asthma (GINA) 2014 guidelines - GINA 4 or 5. 5. ICS dose =500 mcg of fluticasone equivalent/day. Patients on prednisone or biologic for =3 months would not be excluded as long as they meet the rest of the inclusion criteria. 6. ACQ =1.5 during the screening period. 7. CT mucus score =4 during the screening period. Exclusion Criteria: 1. Acute or chronic parasitic, bacterial, fungal or viral infections that required, or currently requires, hospitalization or antimicrobial treatment during the last four weeks. 2. Acute asthma exacerbation event treated with increased doses of oral, or any dose of intramuscular (IM) or intravenous (IV) corticosteroids within six weeks prior to screening. 3. Other relevant pulmonary diseases (e.g., chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis) requiring treatment within 12 months prior to screening. 4. Alcohol or substance abuse within 12 months prior to screening. 5. Current smoker defined as having smoked at least one cigarette (or pipe, cigar, or cannabis) per day for = 30 days within the three months prior to screening. 6. Ex-smokers with = 15 pack-year smoking history. 7. Patient has an implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist). 8. In the investigator's opinion, subject suffers from any physical, psychological, or other condition(s) that might prevent performance of the MRI, such as severe claustrophobia. 9. Pregnant or breastfeeding 10. Participation in any clinical trial of an investigational agent or procedure within three months prior to screening or during the study. |
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Healthcare Hamilton | Hamilton | Ontario |
Canada | Western University | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
St. Joseph's Healthcare Hamilton | Trudell Medical International |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Sputum rheology | Change from screening/baseline (week 0) to week 16 in expectorated sputum rheology (critical stress, elastic modulus, viscous modules) | 16 weeks | |
Other | Mucin proteins in sputum | Change from screening/baseline (week 0) to week 16 in mucin proteins in sputum (MUAC5, MUCSB, MUC5AC:MUC5B ratio). | 16 weeks | |
Primary | Computed Tomography (CT) mucus score | Change in the CT mucus score between screening/baseline (week 0) and week 16. Mucus scores range from 0 (best outcome) to 20 (worst outcome). | 16 weeks | |
Secondary | MRI ventilation defect percent (VDP) | Change in MRI VDP between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | Forced expiratory volume in one second (FEV1) | Change in FEV1 between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | Asthma Control Questionnaire-5 (ACQ-5) | Change in ACQ-5 between screening/baseline (week 0) and week 16. ACQ-5 ranges from 0 (best outcome) to 5 (worst outcome). | 16 weeks | |
Secondary | Asthma Quality of Life Questionnaire (AQLQ) | Change in AQLQ between screening/baseline (week 0) and week 16. AQLQ ranges from 1 (worst outcome) to 7 (best outcome). | 16 weeks | |
Secondary | Asthma Control Test (ACT) | Change in ACT between screening/baseline (week 0) and week 16. ACT ranges from 5 (worst outcome) to 25 (best outcome). | 16 weeks | |
Secondary | Cough and Sputum Assessment Questionnaire (CASA-Q) | Change in CASA-Q between screening/baseline (week 0) and week 16. The scores for each domain range from 0 to 100, with higher scores indicating fewer/less severe symptoms and less impact. | 16 weeks | |
Secondary | St. George's Respiratory Questionnaire (SGRQ) | Change in SGRQ between screening/baseline (week 0) and week 16. SGRQ scores range from 0 to 100, with higher scores indicating more limitations. | 16 weeks | |
Secondary | fraction of exhaled nitric oxide (FeNO) | Change in FeNO between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | blood eosinophil count | Change in blood eosinophil count between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | sputum eosinophil percent | Change in sputum eosinophil percent between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | sputum neutrophil percent | Change in sputum neutrophil percent between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | inspiratory CT wall area percent (WA%) | Change in CT WA% between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | inspiratory CT lumen area (LA) | Change in CT LA between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | respiratory system resistance (Rrs) at 5Hz | Change in Rrs5Hz between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | respiratory system reactance (Xrs) at 5Hz | Change in Xrs5Hz between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | respiratory system resistance (Rrs) at 19Hz | Change in Rrs19Hz between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | frequency dependence of Rrs (Rrs5-19Hz) | Change in Rrs5-19Hz between screening/baseline (week 0) and week 16. | 16 weeks | |
Secondary | integrated area of low frequency reactance (AX) | Change in AX between screening/baseline (week 0) and week 16. | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|